Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Authors: Harry Heijerman, Edward F. McKone, D.G. Downey, Eva Van Braeckel, Steven M. Rowe, Elizabeth Tullis, Marcus Mall, John Welter, Bonnie W. Ramsey, Charlotte McKee, Gautham Marigowda, Samuel M. Moskowitz, David Waltz, Patrick R. Sosnay, C Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L. Taylor‐Cousar, Karen McCoy, Karen McCoy, Scott H. Donaldson, Seth Walker, James F. Chmiel, Ronald C. Rubenstein, Deborah Froh, Isabel P. Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor‐Cousar, Bruce Barnett, Gary A. Mueller, Patrick A. Flume, F. R. Livingston, Nighat Mehdi, Charlotte C. Tenebäck, John Welter, Raksha Jain, Dana G. Kissner, K. Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas G. Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross C. Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, D.G. Downey, Gary Connett, E.F. Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, F. Vermeulen, Eva Van Braeckel, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof J. Majoor - The Lancet 2019 cited by 1,367